KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is still one of the deadliest cancers in oncology because of its increasing incidence and poor survival rate. More than 90% of PDAC patients are KRAS mutated (KRASmu), with KRASG12D and KRASG12V being the most common mutations. Despite this critical role, its characteristics have made direct targeting of the RAS protein extremely difficult. KRAS regulates development, cell...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Pancreatic and Hepatic Oncology Research
• Share to PI3K/AKT/mTOR signaling in cancer
• Share to Ubiquitin and proteasome pathways